Akero Therapeutics Inc (AKRO)
49.25
+1.60 (+3.36%)
USD |
NASDAQ |
Jan 27, 16:00
49.22
-0.03 (-0.06%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.286B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 199.6% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 15.41 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
MT Newswires
01/27 09:41
Globe Newswire
01/10 08:00
Globe Newswire
01/04 08:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/24/2023* | -- | Results | Q4 2022 | -- | -0.83 | -- | |
| 11/04/2022 | -- | Results | Q3 2022 | -0.92 | -0.73 | -26.51% | |
| 08/05/2022 | -- | Results | Q2 2022 | -0.77 | -0.86 | 10.96% | |
| 05/06/2022 | -- | Results | Q1 2022 | -0.74 | -0.84 | 11.74% | |
| 02/25/2022 | -- | Results | Q4 2021 | -0.93 | -0.81 | -15.06% | |
| 11/12/2021 | -- | Results | Q3 2021 | -0.70 | -0.91 | 22.80% | |
| 08/13/2021 | -- | Results | Q2 2021 | -0.83 | -0.71 | -17.62% | |
| 05/13/2021 | -- | Results | Q1 2021 | -0.43 | -0.94 | 54.06% |
*Estimated Date/Time
Earnings
Profile
Edit
| Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis. |
| URL | https://www.akerotx.com |
| Investor Relations URL | https://ir.akerotx.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 24, 2023 (est.) |
| Last Earnings Release | Nov. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of January 27, 2023.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 110.44M |
| Net Income (TTM) | -110.19M |
| Total Assets (Quarterly) | 185.68M |
| Total Liabilities (Quarterly) | 37.30M |
| Shareholders Equity (Quarterly) | 148.37M |
| Cash from Operations (TTM) | -83.69M |
| Cash from Investing (TTM) | 68.55M |
| Cash from Financing (TTM) | 35.32M |
Ratings
Profile
Edit
| Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis. |
| URL | https://www.akerotx.com |
| Investor Relations URL | https://ir.akerotx.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 24, 2023 (est.) |
| Last Earnings Release | Nov. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| AKRO Tweets |